Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.85 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.85 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
| ▸ | FABP3 | P05413 | 1/20 | 0.80 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.72 |
| ▸ | SELP | P16109 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28671483 | 0.96 | LPAR3 (0.79) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL21249160 | 0.96 | LPAR3 (0.79) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL14984104 | 0.96 | LPAR3 (0.79) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL12195367 | 0.96 | LPAR3 (0.79) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL15120601 | 0.95 | FABP3 (0.80) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL19821350 | 0.95 | FABP3 (0.80) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL12236914 | 0.95 | FABP3 (0.80) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL15386588 | 0.95 | FABP3 (0.80) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL13013192 | 0.95 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL14793212 | 0.95 | FABP3 (0.80) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315216-A1 | PHOSPHATE COMPOSITION | VANTAGE SPECIALTIES, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315216-A1 | PHOSPHATE COMPOSITION | VANTAGE SPECIALTIES, INC. | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315216-A1 | PHOSPHATE COMPOSITION | PHOSPHO1, PLA2G2C, PLCG2 | LPAR3 252/4885LPAR1 278/4885ENPP2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.